2025-11-07

Q3 2025 Results

2025-08-07

Q2 2025 Results

Financial data not available in provided content

2025-05-07

Q1 2025 Results

Financial data not available in provided XBRL structure

2024-11-12

Q3 2024 Results

2024-08-08

Q2 2024 Results

2024-05-08

Q1 2024 Results

2025-02-28

FY2024 2024 Results

Revenue and EPS data not visible in provided XBRL metadata

2024-02-23

FY2023 2023 Results

2025-11-19

General Counsel Departed

Deborah H. Telman out Dec 5, 2025

2025-10-30

Q3 2025 Earnings

Q3 2025 financial results announced

2025-10-06

Biktarvy Patent Settlement

No generic entry until April 1, 2036

2025-08-14

New Principal Accounting Officer

Erin Burkhart appointed SVP Controllership, effective Sept 22, 2025

2025-08-07

Q2 2025 Earnings

Q2 2025 financial results announced

2025-08-04

Amended Bylaws

Board approved amended bylaws on July 30, 2025

2025-05-08

2025 Annual Shareholder Meeting

9 directors elected, executive compensation approved, 4 shareholder proposals rejected

2025-04-24

Q1 2025 Earnings

Q1 2025 financial results announced

2025-03-12

Chief Accounting Officer Departed

Sandra Patterson out, Diane Wilfong interim CAO

2025-02-11

Q4 2024 Earnings

Financial results for quarter and year ended December 31, 2024

2024-11-20

Debt Offering

$3.5B senior notes: $750M 2029s at 4.80%, $1B 2035s at 5.10%, $1B 2054s at 5.50%, $750M 2064s at 5.60%

2024-11-06

Q3 2024 Earnings

Q3 2024 financial results announced

2024-08-08

Q2 2024 Earnings

Q2 2024 financial results for quarter ended June 30, 2024

2024-07-17

CMO Departure

Merdad V. Parsey, M.D., Ph.D. leaving, transition through Q1 2025

2024-05-09

Annual Shareholder Meeting Results

9 directors elected, officer exculpation amendment approved, 3 shareholder proposals rejected

2024-04-25

Q1 2024 Earnings

Q1 2024 financial results announced

2024-03-22

Acquired CymaBay Therapeutics

$4.3B deal at $32.50 per share

2024-03-14

Director Retirement

Kevin E. Lofton retiring from Board at May 8, 2024 annual meeting

2024-02-12

Acquired CymaBay Therapeutics

$32.50 per share, $151.6M termination fee

2024-02-06

Q4 2023 Earnings

Financial results for quarter and year ended December 31, 2023